Skip to main content

Peer Review reports

From: Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study

Original Submission
9 Nov 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
8 Aug 2023 Reviewed Reviewer Report
7 Nov 2023 Reviewed Reviewer Report
17 Nov 2023 Author responded Author comments - Xichuang Chen
Resubmission - Version 4
17 Nov 2023 Submitted Manuscript version 4
22 Nov 2023 Author responded Author comments - Xichuang Chen
Resubmission - Version 5
22 Nov 2023 Submitted Manuscript version 5
23 Nov 2023 Reviewed Reviewer Report
24 Nov 2023 Reviewed Reviewer Report
26 Nov 2023 Author responded Author comments - Xichuang Chen
Resubmission - Version 6
26 Nov 2023 Submitted Manuscript version 6
Publishing
29 Nov 2023 Editorially accepted
5 Dec 2023 Article published 10.1186/s12913-023-10402-0

You can find further information about peer review here.

Back to article page